FCGRT and myasthenia gravis: It provides preliminary evidence that FcRn antagonists may represent an optimal salvage therapy for refractory MG cases involving multiple pathogenic antibodies, particularly in clinical settings demanding: (1) rapid immunomodulation, (2) avoidance of invasive procedures, and (3) minimization of treatment-related comorbidities.